| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.35 | 2e-29 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | 0.2 | 1e-11 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.31 | 2e-11 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | 0.21 | 1e-10 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.27 | 2e-10 |
| mRNA | ATRA | FIMM | pan-cancer | AAC | 0.88 | 5e-10 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.21 | 1e-09 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.24 | 5e-09 |
| mRNA | selumetinib:tretinoin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.2 | 7e-09 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | 0.19 | 1e-08 |